- Aug 2022
-
www.medrxiv.org www.medrxiv.org
-
Regev-Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S., Meltzer, L., Asraf, K., Cohen, C., Fluss, R., Biber, A., Nemet, I., Kliker, L., Joseph, G., Doolman, R., Mendelson, E., Freedman, L. S., Harats, D., Kreiss, Y., & Lustig, Y. (2022). 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC (p. 2022.02.15.22270948). medRxiv. https://doi.org/10.1101/2022.02.15.22270948
-
- Apr 2022
-
twitter.com twitter.com
-
Freja Kirsebom. (2022, January 28). Two important updates from our team this week: - Vaccine effectiveness (VE) against symptomatic disease after Omicron BA.2 shows that VE remains unchanged—VE against death after Omicron BA.1 shows VE is 95% at 2+ weeks after booster 1/7 Full report https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050721/Vaccine-surveillance-report-week-4.pdf [Tweet]. @freja_kirsebom. https://twitter.com/freja_kirsebom/status/1486730977464369160
-
-
www.covid-datascience.com www.covid-datascience.com
-
Morris, J. (2021, August 17). Israeli data: How can efficacy vs. severe disease be strong when 60% of hospitalized are vaccinated? Covid Data Science. https://www.covid-datascience.com/post/israeli-data-how-can-efficacy-vs-severe-disease-be-strong-when-60-of-hospitalized-are-vaccinated
Tags
- age
- dose
- is:blog
- efficacy
- variant
- Pfizer
- asymptomatic
- delta
- surge
- effective
- severe disease
- lang:en
- vaccine
- symptomatic
- hospitalization
- risk
- COVID-19
Annotators
URL
-
- Feb 2022
-
www.bmj.com www.bmj.com
-
Mahase, E. (2022). Omicron sub-lineage BA.2 may have “substantial growth advantage,” UKHSA reports. BMJ, 376, o263. https://doi.org/10.1136/bmj.o263
-
- Jan 2022
-
twitter.com twitter.com
-
ReconfigBehSci on Twitter: “RT @AliHMokdad: Vaccine effectiveness against BA.1 and BA.2. After 2 doses it was 9% (7-10%) and 13% (-26-40%) respectively for BA.1 and BA…” / Twitter. (n.d.). Retrieved January 30, 2022, from https://twitter.com/SciBeh/status/1487123660771106821
-
- Jun 2021
-
www.theguardian.com www.theguardian.com
-
Covid variants: How much protection do the different vaccines offer? (2021, June 3). The Guardian. http://www.theguardian.com/world/2021/jun/03/covid-variants-delta-alpha-how-much-protection-vaccines
Tags
- vaccination
- infection
- restriction
- death
- efficacy
- variant
- effectiveness
- pandemic
- delta
- is:news
- protection
- trial
- lang:en
- vaccine
- rate
- symptomatic
- data
- England
- lift
- disease
- COVID-19
Annotators
URL
-
- Mar 2021
-
twitter.com twitter.com
-
A Marm Kilpatrick. (2021, February 9). Vaccine efficacy in blocking infection & transmission (I think) We can now estimate the (minimum) reduction in transmission from the Moderna vaccine. Thread tl;dr Moderna vaccine blocks >90% (87-93%) of infections & 91% (89-94%) of transmission. *Critiques welcome! Https://t.co/GjQIo3v4oe [Tweet]. @DiseaseEcology. https://twitter.com/DiseaseEcology/status/1359213735424872450
-
-
www.thelancet.com www.thelancet.com
-
Olliaro, P. (2021). What does 95% COVID-19 vaccine efficacy really mean? The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00075-X
-
-
www.nature.com www.nature.com
-
Pullano, G., Di Domenico, L., Sabbatini, C. E., Valdano, E., Turbelin, C., Debin, M., Guerrisi, C., Kengne-Kuetche, C., Souty, C., Hanslik, T., Blanchon, T., Boëlle, P.-Y., Figoni, J., Vaux, S., Campèse, C., Bernard-Stoecklin, S., & Colizza, V. (2021). Underdetection of cases of COVID-19 in France threatens epidemic control. Nature, 590(7844), 134–139. https://doi.org/10.1038/s41586-020-03095-6
-
- Jul 2020
-
www.thelancet.com www.thelancet.com
-
Mei, Q., Li, J., Du, R., Yuan, X., Li, M., & Li, J. (2020). Assessment of patients who tested positive for COVID-19 after recovery. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(20)30433-3
-